COBRE: Eukaryotic Pathogens Innovation Center (EPIC)
COBRE:真核病原体创新中心(EPIC)
基本信息
- 批准号:10494462
- 负责人:
- 金额:$ 220.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-15 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:Advisory CommitteesAfrican TrypanosomiasisAmebic colitisAntifungal AgentsAntiparasitic AgentsAreaAspergillosisAspergillus fumigatusAssistantshipAwardAzolesBioinformaticsBiologyBioterrorismCardiovascular DiseasesCell SeparationCenters of Research ExcellenceChagas DiseaseClassificationCollaborationsColon CarcinomaCommunicable DiseasesCommunicationComplexCountryCryptococcusDetectionDevelopmentDiagnosisDiseaseDynein ATPaseDysenteryEducational workshopEnvironmentEnvironmental Risk FactorEquipmentEvolutionFacultyFaculty RecruitmentFosteringFundingFungal MeningitisGenomicsGoalsGovernmentGrantHelminthsHost DefenseHumanIncidenceInfectionInfrastructureInterdisciplinary StudyKnowledgeLeadershipLightMalariaMedicalMeningitisMentorsModelingMusculoskeletal DiseasesParasitesParasitic DiseasesPhasePilot ProjectsPostdoctoral FellowPovertyProbabilityProgram Research Project GrantsRegulationResearchResearch PersonnelResource AllocationRoleScientistSouth CarolinaStrokeStudent recruitmentToxoplasmosisTrainingTrichomonas InfectionsTrypanosomaUnited States National Institutes of HealthUniversitiesVaccinesVirulenceZebrafishbasecellular imagingclimate changecollegedietary supplementsdrug discoveryemerging pathogengraduate studenthuman diseaseimaging facilitiesinnovationinsightlipidomicsmacrophagemembermultidisciplinaryneglectneglected tropical diseasesoxidant stresspathogenprimary amebic meningoencephalitisprogramsrecruitresponseskillssuccesstargeted treatmenttenure tracktissue regenerationtransmission processvector
项目摘要
PROJECT SUMMARY/ABSTRACT
Eukaryotic pathogens are the causative agents of some of the most devastating and intractable diseases of
humans, including malaria, amebic dysentery, African sleeping sickness, Chagas disease, trichomoniasis,
aspergillosis, cryptococcal fungal meningitis, toxoplasmosis and primary amebic meningoencephalitis (PAM).
The global impact of these diseases is immense. It is noteworthy that many of these pathogens are the causative
agents of neglected tropical diseases (NTDs), neglected diseases of poverty (NDPs) and/or are classified as
bioterrorism agents. Importantly, infections caused by eukaryotic pathogens are increasing in the US due to
globalization. The primary goal of this COBRE proposal is to increase the number of NIH-funded scientists in the
state of South Carolina by supporting a world-class research center, the Eukaryotic Pathogens Innovation Center
(EPIC), at Clemson University (CU). The scientific focus of EPIC is a multidisciplinary study of important global
eukaryotic pathogens. EPIC is the first-and-only in the state with a focus on infectious diseases, and the first-
and-only in the country with a focus on eukaryotic pathogens. Four projects from target junior investigators will
be supported. Their projects are 1) Regulation mechanisms of Trypanosome brucei axonemal dynein, 2)
Functional roles of ncRNA, afu-182, in azole response and pathobiology of Aspergillus fumigatus, 3)
Investigating the function of macrophages in the efficacy of anti-fungal drugs in larval zebrafish, and 4) Evaluating
anti-parasitic diazacyclobutenes. These investigators will be matched with external and internal mentors who are
established NIH-funded researchers. The projects will be supported by a well-organized Administrative Core and
two state-of-the-art Scientific Cores in Genomics, and Imaging/Cell Sorting. The center also has a substantial
infrastructure base and significant institutional support. For example, CU will recruit two additional faculty
members and two post-doctoral fellows to expand activities of this center over the course of the project period.
Pledges of graduate assistantships, equipment, and space further exemplify the institutional commitment. The
continuation of this COBRE-funded center will significantly expand research in South Carolina and will facilitate
recruitment, training, and retention of a critical mass of investigators with cross-disciplinary skills in this important
research area.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES Culvin MORRIS其他文献
JAMES Culvin MORRIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES Culvin MORRIS', 18)}}的其他基金
Enolase inhibitors as therapeutic leads for Naegleria fowleri infections
烯醇酶抑制剂作为福氏耐格里阿米巴感染的治疗先导药物
- 批准号:
10739388 - 财政年份:2023
- 资助金额:
$ 220.95万 - 项目类别:
Approaches for genetic manipulation of Naegleria fowleri
福氏耐格里虫的基因操作方法
- 批准号:
10641130 - 财政年份:2023
- 资助金额:
$ 220.95万 - 项目类别:
COBRE: Eukaryotic Pathogens Innovation Center (EPIC)
COBRE:真核病原体创新中心(EPIC)
- 批准号:
10666653 - 财政年份:2022
- 资助金额:
$ 220.95万 - 项目类别:
Acquisition of the Agilent Cytation C10 confocal imaging reader for enhancing biomedical research excellence at Clemson University
采购 Agilent Cytation C10 共焦成像阅读器,以提高克莱姆森大学的生物医学研究卓越性
- 批准号:
10798537 - 财政年份:2022
- 资助金额:
$ 220.95万 - 项目类别:
Nutrient sensing and hexokinases in T. brucei
T. brucei 中的营养感应和己糖激酶
- 批准号:
7911534 - 财政年份:2009
- 资助金额:
$ 220.95万 - 项目类别:
Nutrient Sensing and Hexokinases in T. brucei
布氏锥虫的营养感应和己糖激酶
- 批准号:
8229951 - 财政年份:2008
- 资助金额:
$ 220.95万 - 项目类别:
Nutrient sensing and hexokinases in T. brucei
T. brucei 中的营养感应和己糖激酶
- 批准号:
7454845 - 财政年份:2008
- 资助金额:
$ 220.95万 - 项目类别:
Identification of Inhibitors of Trypanosoma Brucei Hexokinases
布氏锥虫己糖激酶抑制剂的鉴定
- 批准号:
7459260 - 财政年份:2007
- 资助金额:
$ 220.95万 - 项目类别:
Glucose Sensing and Hexokinases in the African Trypanosome
非洲锥虫中的葡萄糖传感和己糖激酶
- 批准号:
9900822 - 财政年份:
- 资助金额:
$ 220.95万 - 项目类别:
Glucose Sensing and Hexokinases in the African Trypanosome
非洲锥虫中的葡萄糖传感和己糖激酶
- 批准号:
9261578 - 财政年份:
- 资助金额:
$ 220.95万 - 项目类别:
相似海外基金
The catalytic core of the proteasome as a drug target to treat Human African Trypanosomiasis
蛋白酶体的催化核心作为治疗非洲人类锥虫病的药物靶点
- 批准号:
10511408 - 财政年份:2022
- 资助金额:
$ 220.95万 - 项目类别:
A One Health approach to investigating the ecology of East African trypanosomiasis in Malawian wildlife
调查马拉维野生动物中东非锥虫病生态学的“同一个健康”方法
- 批准号:
476178 - 财政年份:2022
- 资助金额:
$ 220.95万 - 项目类别:
Studentship Programs
The catalytic core of the proteasome as a drug target to treat Human African Trypanosomiasis
蛋白酶体的催化核心作为治疗非洲人类锥虫病的药物靶点
- 批准号:
10677879 - 财政年份:2022
- 资助金额:
$ 220.95万 - 项目类别:
Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis
多目标方法合理设计非洲人类锥虫病新疗法
- 批准号:
10466942 - 财政年份:2021
- 资助金额:
$ 220.95万 - 项目类别:
Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis
多目标方法合理设计非洲人类锥虫病新疗法
- 批准号:
10296873 - 财政年份:2021
- 资助金额:
$ 220.95万 - 项目类别:
Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis
多目标方法合理设计非洲人类锥虫病新疗法
- 批准号:
10706306 - 财政年份:2021
- 资助金额:
$ 220.95万 - 项目类别:
Reducing and replacing the animal cost of functional genetics in African trypanosomiasis
减少和替代非洲锥虫病功能遗传学的动物成本
- 批准号:
NC/W001144/1 - 财政年份:2021
- 资助金额:
$ 220.95万 - 项目类别:
Research Grant
Development of new drug for African trypanosomiasis based on elucidation of the mechanism of antiprotozoal action by ribavirin.
基于利巴韦林抗原虫作用机制的阐明,开发治疗非洲锥虫病的新药。
- 批准号:
21K18230 - 财政年份:2021
- 资助金额:
$ 220.95万 - 项目类别:
Grant-in-Aid for Challenging Research (Pioneering)
Development of a novel control measure for African trypanosomiasis based on the blocking of lifecycle progression
基于生命周期进展阻断的非洲锥虫病新型控制措施的开发
- 批准号:
20K07467 - 财政年份:2020
- 资助金额:
$ 220.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Drug-diagnostic co-development in Tropical Medicine, combating Human African Trypanosomiasis
热带医学药物诊断联合开发,抗击非洲人类锥虫病
- 批准号:
18KK0454 - 财政年份:2019
- 资助金额:
$ 220.95万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))